Market Overview

UPDATE: Jefferies Raises PT on Humana Ahead of 2Q Earnings Report

Share:
Related HUM
Healthways Up 100% In The Last Month, But UBS Says Sell
Argus Talks Humana-Aetna Deal Uncertainty, Raises EPS Estimates For Humana
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2016 Update (Seeking Alpha)

In a report published Wednesday, Jefferies analyst David Windley reiterated a Buy rating on Humana (NYSE: HUM), and raised the price target from $95.00 to $98.00.

In the report, Jefferies noted, “We expect MCOs to report 2Q earnings upsides. MCO commentary suggests utilization remains favorable, corroborated by Tenet's weak inpatient volumes and ISRG's weak capital equipment sales. We also highlight hot topics and headlines ahead of a flurry of important events over the next several months. AET remains our top MCO pick. We are modestly raising PTs for Diversifieds (still trading at a discount) on more stable outlooks.”

Humana closed on Tuesday at $85.18.

Latest Ratings for HUM

DateFirmActionFromTo
Aug 2016Credit SuisseMaintainsNeutral
Aug 2016JefferiesMaintainsBuy
Aug 2016BarclaysMaintainsEqual-weight

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: David Windley JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (HUM)

View Comments and Join the Discussion!